On the other hand, in advanced stages, the blockade of immune checkpoints has opened up a new standard of treatment for cancer patients, producing an effective antitumor response in tumor microenvironment (TME), concretely PD1/PDL1 axis inhibitors have been extensively studied and have drastically changed the therapeutic scenario for NSCLC with a plethora of clinical data demonstrating superior outcomes related to conventional therapies or molecular targeted therapy [6, 7, 8, 9]. Here, CD274 is linked to non-small cell lung carcinoma.